Citations

Clear

278 citation(s) found for "Sy, Ethan".

Effect of premorbid body mass index on mortality in patients with lung cancer: A systematic review and meta-analysis.
Arora, Nivedita , Singh, Siddharth , Johnson, David H. , Gupta, Arjun , Majumder, Kaustav, Mayo, Helen , Singh, Preet Paul , Halm, Ethan A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8523-8523

10.1200/jco.2016.34.15_suppl.8523 Get It

Academic and Community Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Polley, Mei‐Yin C. , Hurria, Arti , Muss, Hyman B. , Ruddy, Kathryn J. , Liu, Heshan , Rogak, Lauren J. , Basch, Ethan , Dakhil, Shaker R. , Huff, Jason D., Bajaj, Madhuri, Wilkinson, Mary, Baghadadi, Tareq Al, Benjamin, Sam, Mowat, Rex B., Hudis, Clifford A. , Freedman, Rachel A. , Dueck, Amylou C. , Hubbard, Joleen M. , Basch, Ethan , Rugo, Hope S. , Winer, Eric P. , Baghdadi, Tareq Al

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS629-TPS629

10.1200/jco.2016.34.15_suppl.tps629 Get It

Patient preference for receiving information about long-term symptoms.
Schleicher, Stephen M. , Basch, Ethan , Sloan, Jeff A. , Blinder, Victoria , Bennett, Antonia V , Eberle, Carolyn E. , Aviki, Emeline Mariam , Patil, Sujata N , Basch, Ethan

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e21681-e21681

10.1200/jco.2017.35.15_suppl.e21681 Get It

e21681 Background: Maintaining quality of life with minimal symptoms is an important goal of cancer treatment. We surveyed patients undergoing cancer treatment about their preferences for information about the long-term symptom burden associated with their current treatment. Methods: Patients undergoing active cancer treatment were enrolled at two large cancer centers from 1/2014 to 7/2015. At the time of enrollment patients reported their household income, employment, performance status and their agreement with the statement, “It would be useful to know the percentage of patients having persistent symptoms more than a year after getting the same treatment I am getting.” Treatment intention (curative vs. palliative) was reported by the treating oncologist. Results: 196 patients completed the survey. The mean age was 55.7 (range 20-80); 54% were female, 69% were white, and 60% were receiving palliative treatment. The majority (83%) of patients either strongly agreed or somewhat agreed that it would be helpful to have information about future symptoms. In univariable analyses, this preference did not significantly differ based on patient-reported performance status, sex, age, treatment intent, race, or household income. Using a more stringent criterion to dichotomize the outcome, 59% of participants strongly agreed that it would be helpful to have information about future symptoms. Patients undergoing treatment with curative intent were significantly more likely to strongly agree (72% vs. 51%, p = 0.0035). In a multivariable analysis adjusting for age, sex, income level, employment status, and patient-reported performance status, participants undergoing curative versus palliative treatment had 3.1 times the odds (95% CI 1.47-6.65) of strongly agreeing. Conclusions: The majority of patients undergoing cancer treatment wanted to know what symptoms to expect in the future, and this was independent of patient demographics. Patients undergoing treatment with curative intent are significantly more likely to want this information than patients undergoing palliative treatment. Symptom data collected through research studies and registries should be summarized by treatment and other key predictors and made available to patients.
A multicenter analysis of patient reported risk factors for not working during cancer therapy.
Blinder, Victoria , Schleicher, Stephen M. , Basch, Ethan , Sloan, Jeff A. , Eberle, Carolyn E. , Aviki, Emeline Mariam , Patil, Sujata N , Basch, Ethan , Bennett, Antonia V

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 6523-6523

10.1200/jco.2017.35.15_suppl.6523 Get It

6523 Background: Treatment for most types of cancer results in work disruptions. The aim of this study is to identify risk factors for not working during cancer therapy using a patient-reported outcome tool. Methods: Patients of all cancer types, who were undergoing treatment with curative or palliative intent, were enrolled in a survey-based study at Memorial Sloan Kettering Cancer Center and the North Carolina Cancer Hospital from 1/2014 to 7/2015. All patients working full- or part- time at the time of cancer diagnosis were included in this analysis. Patient reported outcomes were collected using a survey tool at any time during active cancer treatment. The primary outcome of this analysis was self-reported work status at the time of survey completion. Results: Of 119 patients who were working before their cancer diagnosis, 68% were working at the time of survey completion. The mean age was 52.9 (range 20-80). Younger age was associated with working: 82% of patients age < 40 were working during treatment vs. 31% of patients age > 65 (p=0.01). The number of days patients reported being completely unable to work in the past month was significantly associated with work status; only 26% of patients who missed > 10 days continued to work compared to 69% who missed ≤ 10 days (p<0.01). Patients who report having a flexible work schedule were 23% more likely to continue to work during treatment (69% vs. 46%, p=0.01). In a multivariable model controlling for having an employer contingent health plan, and household income > 200% of the federal poverty level (fpl), only age, having a flexible work schedule, and inability to work > 10 days were independently associated with work status during treatment (Table). Conclusions: Having a flexible work schedule allowed for more work interruptions without job loss. Patients who are likely to miss more than 10 days of work and who have inflexible work schedules are at high risk of unemployment and should be targeted for employment retention initiatives. [Table: see text]
Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.
Basch, Ethan , Deal, Allison M. , Atkinson, Thomas M. , Scher, Howard I. , Hudis, Clifford A. , Sabbatini, Paul , Rogak, Lauren J. , Basch, Ethan , Deal, Allison , Dueck, Amylou C. , Bennett, Antonia V , Kris, Mark G. , Dulko, Dorothy , Leahy, Allison Barz , Schrag, Deborah

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: LBA2-LBA2

10.1200/jco.2017.35.15_suppl.lba2 Get It

LBA2 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Sunday, June 4, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer.
Long, Beverly, Hou, Xiaonan , Becker, Marc A., VanBlaricom, Jamison L., Bradley, Evans, Hendrickson, Andrea E. Wahner , Oberg, Ann L. , Heinzen, Ethan P. , Camoriano, John , Colón‐Otero, Gerardo , Burton, Jill K., Kalli, Kimberly R., Foster, Nathan R. , Weroha, Saravut J., Maurer, Matthew J. , Haluska, Paul

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS5609-TPS5609

10.1200/jco.2016.34.15_suppl.tps5609 Get It

Randomized trial comparing a web-mediated follow-up via patient-reported outcomes (PRO) vs. routine surveillance in lung cancer patients: Final results.
Denis, Fabrice , Basch, Ethan , Lethrosne, Claire, Pourel, N. , Molinier, Olivier , Pointreau, Y. , Dômont, Julien , Bourgeois, Hugues , Senellart, Hélène, Urban, T. , Septans, Anne-Lise , Balavoine, Magal, Solal‐Céligny, Philippe , Basch, Ethan , Bennouna, Jaafar , Balavoine, Magali , Dueck, Amylou C. , Letellier, Christophe

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 6500-6500

10.1200/jco.2018.36.15_suppl.6500 Get It

Temporal lobe contusions on computed tomography are associated with impaired 6-month functional recovery after mild traumatic brain injury: a TRACK-TBI study
Yue, John K. , Winkler, Ethan A. , Puffer, Ross C. , Deng, Hansen , Wagle, Sagar, Morrissey, Molly Rose, Rivera, Ernesto J. , Runyon, Sarah J., Vassar, Mary J. , Taylor, Sabrina R. , Cnossen, Maryse C. , Lingsma, Hester F. , Yuh, Esther L. , Schnyer, David M. , Puccio, Ava M. , Valadka, Alex B. , Okonkwo, David O. , Manley, Geoffrey T. , Investigators, the TRACK-TBI, Schnyer, David M , Phelps, Ryan , Mukherjee, Pratik

Mayo Clinic

Neurological Research | September 3, 2018 | Volume: 40 | Issue: 11 | Pages: 972-981

10.1080/01616412.2018.1505416 | PMID 30175944 Get It

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials
Bottomley, Andrew , Pe, Madeline , Sloan, Jeff A. , Basch, Ethan , Bonnetain, Franck, Calvert, Melanie , Campbell, Alicyn, Cleeland, Charles S. , Cocks, Kim , Collette, Laurence , Dueck, Amylou C. , Flechtner, Hans‐Henning , Gotay, Carolyn , Greimel, Eva , Griebsch, Ingolf , Grøenvold, Mogens , Hamel, Jean-François, King, Madeleine , Koller, Michael , Malone, Daniel C. , Martinelli, Francesca , Moinpour, Carol M. , Musoro, Jammbe , O’Connor, Daniel , Oliver, Kathy , Piault‐Louis, Elisabeth, Piccart, Martine , Pimentel, Francisco , Quinten, Chantal , Reijneveld, Jaap C. , Soltys, Katherine M, Sridhara, Rajeshwari , Taphoorn, Martin , Velikova, Galina , Coens, Corneel , Sloan, Jeff, Flechtner, Hans-Henning , Dueck, A. C. , Basch, Ethan , Devlin, Nancy J. , Kluetz, Paul Gustav , Mitchell, Sandra A , Schürmann, Christoph, Smith, Ashley Wilder

Mayo Clinic

Clinical Trials | August 24, 2018 | Volume: 15 | Issue: 6 | Pages: 624-630

10.1177/1740774518795637 | PMID 30141714 Get It

Background There is currently a lack of consensus on how health-related quality of life and other patient-reported outcome measures in cancer randomized clinical trials are analyzed and interpreted. This makes it difficult to compare results across randomized controlled trials (RCTs) synthesize scientific research, and use that evidence to inform product labeling, clinical guidelines, and health policy. The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data for Cancer Clinical Trials (SISAQOL) Consortium aims to develop guidelines and recommendations to standardize analyses of patient-reported outcome data in cancer RCTs. Methods and Results Members from the SISAQOL Consortium met in January 2017 to discuss relevant issues. Data from systematic reviews of the current state of published research in patient-reported outcomes in cancer RCTs indicated a lack of clear reporting of research hypothesis and analytic strategies, and inconsistency in definitions of terms, including “missing data,”“health-related quality of life,” and “patient-reported outcome.” Based on the meeting proceedings, the Consortium will focus on three key priorities in the coming year: developing a taxonomy of research objectives, identifying appropriate statistical methods to analyze patient-reported outcome data, and determining best practices to evaluate and deal with missing data. Conclusion The quality of the Consortium guidelines and recommendations are informed and enhanced by the broad Consortium membership which includes regulators, patients, clinicians, and academics.
Abstract 5240: Functional and therapeutic significance of ESR1 gene fusions in breast cancer
Shao, Jieya , Iglesia, Michael D. , Chan, Doug W. , Jin, Cao , Singh, Purba , He, Xiaping , Kosaka, Yoshimasa , Matsunuma, Ryoichi , Crowder, Robert J., Phommaly, Chanpheng, Gonçalves, Rodrigo , Romalho, Susana, Peres, Raquel Mary Rodrigues , Punturi, Nindo , Schmidt, Cheryl, Bartram, Alex, Jou, Eric , Lai, W V., Rogers, Anna , Tobias, Ethan, Parikh, Poojan A., Li, Shunqiang , Cynthia, X. , Thompson, Emily A. , Kavuri, Shyam M. , Creighton, Chad J. , Maher, Christopher A. , Haricharan, Svasti , Lei, Jonathan T. , Zhang, Jin , Anurag, Meenakshi , Hoog, Jeremy , Lai, W V., Hampton, Oliver , Davies, Sherri R. , Suman, Vera J. , Hunt, Kelly K. , Watson, Mark A. , Hoadley, Katherine A. , Thompson, E A., Chen, Xi , Perou, Charles M. , Ellis, Matthew J.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 5240-5240

10.1158/1538-7445.am2018-5240 Get It

Abstract RNA sequencing detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor positive (ER+) breast cancer but their role in disease pathogenesis remains unclear. Herein we examined multiple in-frame and out-of-frame ESR1 fusions and found only two, both identified in advanced endocrine treatment resistant disease, encoded stable and functional in-frame fusion proteins. In both examples, ESR1-e6&gt;YAP1 and ESR1-e6&gt;PCDH11X, the N-terminal, DNA binding and dimerization motifs encoded by exons 2-6 were fused to C-terminal sequences from the partner gene. Functional properties included estrogen-independent growth, constitutive expression of ER target genes, anti-estrogen resistance, induction of cellular motility in vitro and the development of lung metastasis in vivo. Chromatin immunoprecipitation and RNA sequencing experiments showed both fusions uniquely activated a metastasis-associated transcriptional program. ESR1-e6&gt;YAP1 and ESR1-e6&gt;PCDH11X-induced growth remained sensitive to a CDK4/6 inhibitor, palbociclib, and a patient-derived xenograft (PDX) expressing the ESR1-e6&gt;YAP1 fusion was also responsive. Transcriptionally active ESR1 fusions therefore trigger both endocrine therapy resistance and metastatic progression explaining the association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be effective. Citation Format: Jonathan T. Lei, Jieya Shao, Jin Zhang, Michael Iglesia, Doug W. Chan, Jin Cao, Meenakshi Anurag, Purba Singh, Xiaping He, Yoshimasa Kosaka, Ryoichi Matsunuma, Robert Crowder, Jeremy Hoog, Chanpheng Phommaly, Rodrigo Goncalves, Susana Romalho, Raquel M. Peres, Nindo Punturi, Cheryl Schmidt, Alex Bartram, Eric Jou, W V. Lai, Oliver Hampton, Anna Rogers, Ethan Tobias, Poojan Parikh, Sherri R. Davies, Shunqiang Li, Cynthia X. Ma, Vera Suman, Kelly K. Hunt, Mark A. Watson, Katherine A. Hoadley, E A. Thompson, Xi Chen, Shyam M. Kavuri, Chad J. Creighton, Christopher A. Maher, Charles M. Perou, Svasti Haricharan, Matthew J. Ellis. Functional and therapeutic significance of ESR1 gene fusions in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5240.